Nature Reviews Neurology

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	548
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	346
Lymphatic propagation of α-synuclein	346
Brain stimulation aids walking after spinal injury	310
ANA2025 marks important milestones for the ANA and NINDS	258
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	256
Refining oxytocin therapy for autism: context is key	236
Reply to ‘Perils and pitfalls of near-death experience research’	233
Ventricular enlargement caused by aducanumab	228
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	226
Global synergistic actions to improve brain health for human development	220
Neural cell state shifts and fate loss in ageing and age-related diseases	213
Microglia, spreaders of Aβ seeds	209
NODDI reveals brain microstructural changes in multiple sclerosis	206
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	205
Disease-specific modifications of tau protein	183
Continuous levodopa production by an artificial enzyme	166
Imperatives and co-benefits of research into climate change and neurological disease	156
TREM2 mediates phagocytosis in glioblastoma	150
Study reveals new ALS risk genes	143
SEQUINS — a new initiative to address disparities in neurology	138
Nir Giladi (1955–2024)	134
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	132
Spinal muscular atrophy treatment in utero	132
The impact of rare genetic variants on Alzheimer disease	126

Mitochondrial DNA instability in Huntington disease	116
The Digitized Memory Clinic	112
The role of the gut microbiota in multiple sclerosis	110
Psychosis-causing lesions mapped to a hippocampal circuit	108
Neuroinflammation predicts cognitive decline in FTD	106
Ultrasound lets gene therapy into the brain	105
Implications of AD plasma and PET biomarker discordance	105
Menopause influences tau pathology	103
Role for endogenous retrovirus in FTD	102
Brain volume is associated with cognition in MS	94
Amyloid plaques: hotspots for microglial turnover	91
Neurological care for LGBT+ people	91
Challenges of combining multimodal data in assessment of people with traumatic brain injury	89
MRI-based deep learning for TLE diagnosis	89
Diversity, equity and inclusion in neurology	87
Brain imaging illuminates cognitive impairment in multiple sclerosis	84
Gene therapy for seizures in focal cortical dysplasia	83
Management of freezing of gait — mechanism-based practical recommendations	80
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	79
Author Correction: Viral pathogens increase risk of neurodegenerative disease	77
First trials test targeting of α-synuclein for Parkinson disease	75
Precision neuroimmunology in multiple sclerosis — the horizon is near	70
Parkinson disease pathology can originate in the kidney	70
APOE ε4 influences Parkinson disease progression	69
The challenges of anti-tau therapeutics in Alzheimer disease	68
α-Synuclein pathology as a target in neurodegenerative diseases	68
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	63
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	62
Food is brain medicine — relevance and translation to neurology	61
Glymphatic dysfunction in PD clinical progression	60
Neurosteroids alleviate seizures in rats	60
Evidence for altered astrocyte function in Duchenne muscular dystrophy	60
A new biological classification for Parkinson disease	59
Addressing disparities in neurology by building the workforce in LMICs	58
Ultrasound ablation treatment for PD	57
Thalamic inflammation — a therapeutic target for brain injury?	56
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	55
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	55
Coeliac disease as a model for understanding multiple sclerosis	52
Spinal cord stimulation for the treatment of chronic pain	52
New IDEAS about amyloid, race and dementia disparities	52
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	50
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	49
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	49
The global and regional burden of diabetic peripheral neuropathy	48
From the prodromal stage of multiple sclerosis to disease prevention	48
Synaptic degeneration in Alzheimer disease	46
The role of glial cells in multiple sclerosis disease progression	45
Oligomeric tau could spread through synapses in AD	44
Exosomal microRNA is promising biomarker in PD	44

X-chromosome variants and PD in Latin America	44
Is Alzheimer disease a disease?	44
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	43
Hypothyroidism is associated with dementia risk	43
Neurofilament light chain induces neuroinflammation	42
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	42
Cognitive impairment and World Trade Centre-related exposures	41
Neurology in 2025 — reflections from Africa	40
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	40
Global epidemiology of migraine and its implications for public health and health policy	40
Risk locus for paediatric astrocytoma identified	39
The inter-relationship between delirium and dementia: the importance of delirium prevention	39
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	39
α-Synuclein seeds in amyotrophic lateral sclerosis	38
Dual function of biomolecular condensates	38
Moving towards meaningful patient and public engagement	38
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	37
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	36
Prognostic plasma biomarkers for spinal cord injury	36
Change in stroke outcomes over 20 years	36
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	34
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	34
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	34
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	33
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	32
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	31
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	31
CAR T cells offer hope in glioblastoma	30
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	29
Neurology in 2025 — reflections from the USA	27
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	26
Origins and immunopathogenesis of autoimmune central nervous system disorders	26
Huntington disease-like 2: insight into neurodegeneration from an African disease	26
New developments in guidelines for brain death/death by neurological criteria	26
Neurogenesis altered in multiple neurodegenerative diseases	25
High rate of epilepsy in young individuals who died with COVID-19	25
Twin study probes non-heritable immune aspects of multiple sclerosis	24
Does antiherpetic antiviral therapy reduce the risk of dementia?	23
Serum NfL as an MS biomarker	23
John Q. Trojanowski	22
Aberrant protein networks in Alzheimer disease	21
ALS pathogenesis linked to actin barrier collapse	21
AI aces diagnosis of chronic ataxias	20
BCAS1+ oligodendrocytes aid remyelination in MS	20
Pharmacological rehabilitation for stroke	19
Author Correction: The complex aetiology of cerebral palsy	18
Addressing disparities in the global epidemiology of stroke	18
Alzheimer disease in African American individuals: increased incidence or not enough data?	18
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	18
AI and protein structure and function in neurological disease: relevance to disease management	17
The murky waters of sex differences in post-stroke cognitive impairment	17
Neuroprognostication: a conceptual framework	17
Genome-wide analysis furthers decoding of Alzheimer disease genetics	16
Molecular biomarkers for vascular cognitive impairment and dementia	16
Charting brain development across the human lifespan	16
Pathogenetic mechanisms and treatment targets in cerebral malaria	16
Clocking the age of Parkinson disease onset	15
Nusinersen treatment response markers	15
Effects of diet on MS onset and course	15
Altered muscle cholesterol transport in ALS	14
From adaptive deep brain stimulation to adaptive circuit targeting	13
Nanoprobe for blood–brain barrier changes	12
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	12
Predictive tools in psychosis: what is ‘good enough’?	12
Advancing multiple sclerosis management in older adults	12
Alzheimer disease seen through the lens of sex and gender	12
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	12
Mechanistic insights into the interaction between epilepsy and sleep	12
Shared glial pathology in HD and schizophrenia	11
Sex and gender in neurodevelopmental conditions	11
Multidimensional MRI detects astrogliosis	11
Markers help to predict dementia with Lewy bodies	11
Parkinson disease pathology in inflammatory bowel disease	10
Walking the Talk for Dementia — an experience to break down barriers	10
Advances in the therapeutic algorithm for myasthenia gravis	10
Limitations of neurocentric models for near-death experiences	10
Author Correction: Why functional neurological disorder is not feigning or malingering	10
Alzheimer disease in Down syndrome linked to APOE	9
Artificial intelligence in epilepsy — applications and pathways to the clinic	9
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis	9

Evidence-based clinical care and policy making for schizophrenia	9
Timing of hormone replacement therapy could influence Alzheimer disease risk	9
Seizure-associated changes in the Golgi apparatus	9
Advancing neurogenetics in Africa: past achievements, current developments and shaping the future	8
A global view of the genetic basis of Alzheimer disease	8
Identification of neurons involved in schizophrenia	8
Multisite chronic pain: a risk factor for dementia	8
Inclusion in neurological research: empowering people living with neurological diseases	8
MS drug beneficial in an underrepresented group	8
Immune mechanisms and shared immune targets in neurodegenerative diseases	8
Psychiatric sequelae of traumatic brain injury — future directions in research	8
Vulnerable dopamine neurons identified	8
T cell–microbiome communication influences disease in MS model	8
27-Hydroxycholesterol propagates α-synuclein pathology in Parkinson disease	7
Ageing reduces potential for remyelination in multiple sclerosis	7
Glymphatic dysfunction detected in bvFTD	7
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	7
Peripheral B cells altered in Parkinson disease	7
Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA	7
Novel oxytocin spray is beneficial in ASD	7
Sensory feedback in upper limb prosthetics: advances and challenges	7
PD pathology spread linked to mtDNA damage	7
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets	7
Review and update of the concept of embolic stroke of undetermined source	7
Addressing disparities in neurology by enhancing inclusive practice	6
Breakthrough technology restores function after complete paralysis	6
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	6
Recycling brain scans with AI	6
Dementia risk scores in diverse populations	6
Early-stage Alzheimer disease: getting trial-ready	6
Multifaceted roles of APOE in Alzheimer disease	6
Calcium dysregulation could underlie lysosomal impairment in AD	6
BTK inhibitor falters in multiple sclerosis trials	6
Astrocytes in the initiation and progression of epilepsy	6
Oestrogen receptor variants linked to AD traits	6
Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums	5
From precision diagnosis to precision treatment in epilepsy	5
Functional brain networks in the evaluation of patients with neurodegenerative disorders	5
Publisher Correction: Microglial transcriptomics meets genetics: new disease leads	5
EBV-specific T cells in multiple sclerosis	5
Implications of immunometabolism for smouldering MS pathology and therapy	5
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	5
Engineered TREM2 antibody clears Aβ in mice	5
Monitoring disease onset in amyotrophic lateral sclerosis	5
Stem cells show promise in Parkinson disease	5
Translating lifestyle interventions for optimal brain health in Africa	5
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis	5
Microglial senescence is a potential therapeutic target for Alzheimer disease	5
Oligodendrocyte progenitor cell transplant for MS	5
Closing the loop for patients with Parkinson disease: where are we?	4
Addressing disparities in neurology by identifying gaps in hospital care	4
GluA2 modulator targets excitotoxicity in MS	4
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms	4
Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder	4
Novel plasma markers for Parkinson disease	4
Sleep and circadian disturbances in children with neurodevelopmental disorders	4
Reply to: Questioning the cycad theory of Kii ALS–PDC causation	4
A biomarker for mild cognitive impairment	4
Skin α-synuclein differentiates synucleinopathies	4
New CRISPR-based strategies for Alzheimer disease	4
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	4
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?	4
Identifying molecular targets in trigeminal nociception	4
Women’s neurology: a growing subspeciality to tackle sex and gender disparities	4
Brain–machine interface treats pain in rats	4
Neurology under the midnight sun: EAN Congress 2024 comes to Helsinki	4
Exome sequencing identifies risk variants for AD	3
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	3
Finger-prick blood test for Alzheimer disease	3
Disentangling clinical and biological trajectories of neurodegenerative diseases	3
Environmental–genetic interactions in ageing and dementia across Latin America	3
A tale of race and B cells in multiple sclerosis	3
Glioblastoma tackled with oncolytic virus	3
Genetic generalized epilepsies in adults — challenging assumptions and dogmas	3
WNT receptor variant linked to synaptic degeneration	3
Exosomal microRNAs may aid differential diagnosis of movement disorders	3
‘On-demand’ gene therapy for epilepsy	3
Epstein–Barr virus and MS — a causal link	3
MS drug alters B cell metabolism	3
Why functional neurological disorder is not feigning or malingering	3
Lecanemab trial in AD brings hope but requires greater clarity	3
Spreading depolarization as a therapeutic target in migraine	3
The importance of getting evidence into practice	3
Bruton tyrosine kinase inhibitors for multiple sclerosis	3
Insights into the toxic effects of mutant huntingtin	3
New local therapy strategies for brain tumours	3
Autoimmune encephalitis-associated epilepsy	3
Pro-inflammatory diet is linked to dementia risk	3
Glioblastomas divert glucose to promote growth	3
Epigenetic clocks and DNA methylation biomarkers of brain health and disease	3
Building an ethnically and racially diverse neurology workforce	2
Extracellular vesicles: translational research and applications in neurology	2
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits	2
Social determinants of health in multiple sclerosis	2
Pain-resolving immune mechanisms in neuropathic pain	2